Intraoral delivery systems: An overview, current status, and future trends

Drug Delivery to the Oral Cavity: Molecules to Market

Volumn , Issue , 2005, Pages 1-40

  Ghosh, Tapash K ^a   Pfister, William R ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b USA)Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85022170191     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (106)

1. Rathbone, M.J. Oral Mucosal Drug Delivery. Marcel Dekker: New York, 1996.
2. Bruney, C. Market report, evolution of breath strips, Soap and Cosmetics, 10-15, August/September, 2003.
3. Sastry, S.V., Ostrander, K., Chu, J.S., Agarwal, V., and Ghosh, T.K. Annual AAPS Symposium: Oral Fast Dispersing Delivery Systems-Recent Advances, Salt Lake City, UT, October 29, 2003.
4. DeFelippis, M.R. Overcoming the challenges of noninvasive protein and peptide delivery, Am. Pharm. Review, 6(4):21-30, 2003.
5. Sobrero, A. Compts Rendus Hebdomadaires des Sciences. De l’Acadamie des Sciences, 24:247-248, 1847.
6. Murrell, W. Nitroglycerin as a remedy for angina pectoros, Lancet, 151:225-227, 1879.
7. de Vries, M.E., Bodde, H.E., Verhoef, J.C., and Junginger, H.E. Developments in buccal drug delivery, Crit. Rev. Ther. Drug Carrier Syst., 8(3), 271-303, 1991.
8. Shojaei, A. Buccal mucosa as a route for systemic drug delivery: A review, J. Pharm. Pharmaceut. Sci., 1:15-30, 1998.
9. Squier, C.A. The permeability of oral mucosa, Crit. Rev. Oral Biol. Med., 2(1):13-32, 1991.
10. Veillard, M.M. Buccal and gastrointestinal drug delivery systems. In Bioadhesion - Possibilities and Future Trends, Gurny, R. and Junginger H.E., eds. Wissenschaftliche Verlagsgesellschaft mbH: Stuttgart, 1990.
11. Zhou, X.H. Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drug, J. Control Rel. 29:239-252, 1994.
12. Gutniak, M.K., Larsson, H., Sanders, S.W., Juneskans, O., Holst, J.J., and Ahren, B. GLP-1 Tablet in type 2 diabetes in fasting and post-prandial conditions, Diabetes Care, 20:1874-1879, 1997.
13. Bodde, E.H., de Vries, M.E., and Junginger, E.H. Mucoadhesive polymers for the buccal delivery of peptides, structure-adhesiveness relationships, J. Control Release, 13:225-231, 1990.
14. Veuillez, F., Kalia, Y.N., Jacques, Y., Deshusses, J., and Buri, P. Factors and strategies for improving buccal absorption of peptides, Eur. J. Pharmaceut. Biopharm., 51:93-109, 2001.
15. Senel, S., Kremer, M., Nagy, K., and Squier, C. Delivery of bioactive peptides and proteins across oral (buccal) mucosa, Curr. Pharm. Biotech., 2:175-186, 2001.
16. Walker, G.F., Langoth, N., and Bernkop-Schnurch, A. Peptidase activity on the surface of porcine mucosa, Int. J. Pharmaceutics, 233:141-147, 2002.
17. Harris, D. and Robinson, J.R. Drug delivery via the mucous membranes of the oral cavity, J. Pharm. Sci., 81:1-10, 1992.
18. CDER Data Standards Manual, Route of Administration, C-DRG-00301, version 002, http://www.fda.gov/cder/dsm/DRG/drg00301.htm (April 14, 1992).
19. Electronic Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations. 2002. http://www.fda.gov/cder/ob/default.htm, Food and Drug Administration, November 27.
20. E2B Route of Administration List (Attachment 2) with ICH-M2 Codes, Ver 1.4, Based on ICH E2b Step 4, 1997. http://www.fda.gov/cder/m2/icsr/routsas4.pdf, December.
21. The National Drug Code Directory, Internet NDC Directory, 2002. http://www.fda. gov/cder/ndc; http://www.fda.gov/cder/ndc/tblroute.txt, September 30.
22. Medical chewing gum, Drug Delivery Technology, 2(5):8, July/August, 2002.
23. Parakh, S.R. and Gothoskar, A.V. A review of mouth dissolving tablet technologies, Pharm. Tech., 92-100, November, 2003.
24. Brown, D. Oral delivery, orally disintegrating tablets-taste over speed, Drug Delivery Tech. 3(6):58-61, September, 2003.
25. Klancke, J. Dissolution testing of orally disintegrating tablets, Dissolution Technol., 6-8, May, 2003.
26. Research and development expenditure in 1998, R&D Directions, 6(1), January, 2000.
27. Zyprexia Zydis, package insert, Eli Lilly, www.lilly.com, 2003.
28. Product performance, Med. Ad. News, 20(2), February, 2001.
29. Drug approvals, Med. Ad. News, 20(8), August, 2001.
30. Elan enhancers cash position, Med. Ad. News, 21(12):11, December, 2002.
31. Fast-dissolving Risperdal in Europe, Med. Ad. News, 21(12):6, December, 2002.
32. Melts-in-the-mouth Excedrin, Med. Ad. News, 21(12):6, December, 2002.
33. First European markets, Remeron SolTab, Med. Ad. News, 21(10):6, October, 2002.
34. Remeron SolTab, R&D Directions, 8(3):59, March, 2002.
35. Amarin announces acceptance for filing of new drug application for Zelepar by Elan, Drug Delivery Tech., 2(5):17, July/August, 2002.
36. Ethylpharm, Viatrix develop oral version of tramadol for Europe, Drug Delivery Tech., 2(6):16, September, 2002.
37. DePalma, A. Oral delivery: Adding value to old and new drugs, Drug Discovery Devel., 5(7):93-94, July/August, 2002.
38. Pather, S.I., Siebert, J.M., Hontz, J., and Khankari, R.K. Enhanced buccal delivery of fentanyl using the OraVescent drug delivery system, Drug Delivery Technol., 1:54-57, October, 2001.
39. Cima Labs announces license & supply agreement with Wyeth, Drug Delivery Technol., 2(6):22, September, 2002.
40. Generex Biotechnology completes proof-of-concept study for buccal heparin, Drug Delivery Technol., 2(4):23, June, 2002.
41. Drug approvals, Med. Ad. News, 19(1):85, January, 2000.
42. Zomig rapid-melt formulation approved in Japan, SCRIPT 2738:27, April 17, 2002.
43. New medicines of 2001 by dose form, Med. Ad. News, 21(2):43, February, 2002.
44. For migraine, R&D Directions, 8(1):75, January, 2002.
45. Walter, P., Curtis, P., Davidson, N., Erikstein, B., L’ Esperance, B., Miller, I., Rapoport, B., and Ruff, P. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: A multicenter, double-masked study, Clin. Therapeutics, 21(3):492-502, 1999.
46. LeBourgeois, J.P., McKenna, C.J., Coster, B., Feyer, P., Franzen, L., Goedhals, L., Marzecki, Z., Souhami, L., Stewart, A., Tonnessen, F., Haigh, C., Mitchell, T., Wilkinson, J.R., and Graham, E. Efficacy of an ondansetron orally disintegrating tablet: A novel oral formulation of this 5-HT(3) receptor antagonist in the treatment of fractionated radiotherapy-induced nausea and emesis. Emesis Study Group for the ondansetron orally disintegrating tablet in radiotherapy, Clin. Onco., 11(5):340-347, 1999.
47. Drug in development, R&D Directions, 8(2):53, February, 2002.
48. Atrix’s dental product gains new markets, Current Drug Discovery, p. 18, June, 2001.
49. For periodontitis, R&D Directions, 7(4):64, April, 2001.
50. Marketing approval, Appl. Clin. Trials, 10(3):19, March, 2001.
51. Product launch, Med. Ad. News, 19(12):4, December, 2000.
52. Waiting in the gate, Med. Ad. News, 21(8):12, August, 2002.
53. For angina, Med. Ad. News 22(1):84, January, 2003.
54. Press release, U.S. Food and Drug Administration approves effective new tool to help smokers quite, GlaxoSmithKline, October 31, 2002.
55. Written communications from Technology Catalyst Inc. International, Falls Church, VA, 2003.
56. Roller, N.W. Lidocaine topical film strip for oral mucosal biopsies, J. Oral Med., 30:55-58, 1975.
57. Danjo, K., Higuchi, F., and Otsuka, A. Release of lidocaine from polymer film dosage forms, Chem. Pharm. Bull. (Tokyo), 43:1759-1763, 1995.
58. Patient information, Chloraseptic relief stripes, cherry, Prestige Brands, International, 2003, http://www.chloraseptic.com.
59. Zengen, Inc. press release. Zengen’s new technology first to deliver drug active ingredients in an oral strip, advancement to revolutionize oral drug delivery. August 22, 2003, http://www.eurekalert.org/pub_releases/2003-08/z-znt082203.php.
60. Borsadia, S.B., O’Halloran, D., and Osborne, L. Oral film technology, Drug Delivery Technol., 3(3):63-66, May, 2003.
61. Horstmann, M., Laux, W., and Hungerbach, S. Rapidly disintegrating sheet-like presentations of multiple dosage units, US Patent 5,629,003, May 13, 1997.
62. Zerbe, H.G., Guo, J.-H., and Serino, A. Water soluble film for oral administration with instant wettability, US Patent, 5,948,430, September 7, 1999.
63. Zerbe, H.G., Guo, J.-H., and Serino, A. Water soluble film for oral administration with instant wettability, US Patent, 6,177,096, January 23, 2001.
64. Zerbe, H.G., Guo, J.-H., and Serino, A. Water soluble film for oral administration with instant wettability, US Patent 6,592,887, July 15, 2003.
65. Chen, L.-L., Pfister, W.R., Renn, D.W., Buranachokpaisan, T., Osborn, J., Tran, H.S., and Tao, L. Compositions and methods for mucosal delivery, US Patent 6,552,024B1, April 22, 2003.
66. Chen, L.H., Buranachokpaisan, L.T. and Pfister, W. Effect of substitution and viscosity of hydroxypropyl methylcellulose on the properties of a quick-dissolving intraoral delivery system, AAPS Eastern Regional Meeting, abstract 6:41, 1999.
67. Cremer, K., Ludwig, K., Anhauser, D., Schumann, K., Steinborn, P., and Bungarten, U. Primary packaging unit for film-like or oblate-like administered shapes. US Patent 6,655,112, December 2, 2003.
68. Chen, L.H., Liang, A., Zheng, X., and Wu, H-L. Quick dissolving oral mucosal drug delivery device with moisture barrier coating, US Patent application, 20030118653A1, June 26, 2003.
69. Chen, L.H., Pfister, W.R., Renn, D.W., Buranachokpaisan, T., Osborne, J., Tan, H.S., and Li, T. Compositions and methods for mucosal delivery, US Patent Application 200300683786, April 10, 2003.
70. Okamoto, H., Taguchi, H., Iida, K., and Danjo, K. Development of polymer film dosage forms of lidocaine for buccal administration. I. Penetration rate and release rate, J Control. Rel., 77:253-260, 2001.
71. Amarin Corporation press release, Amarin Corporation announces acceptance for filing of a new drug application for Zelapar™ by the FDA, May 23, 2002.
72. Amarin Corporation press release, Amarin Corporation announces Zelapar™ receives approvable letter from FDA, February 18, 2003.
73. Clarke, A., Brewer, F., Johnson, E.S., Mailard, N., Hartig, F., Taylor, S., and Corn, T.H. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition, J. Neural Transm., 110:1241-1255, 2003.
74. Zomig ZMT, Med. Ad. News, 20(6):70, June, 2001.
75. Press release, Multimedia available: FDA approves over-the-counter loratadine drug Alavert, Business Wire, Friday, December 20, 2002.
76. Lingual (Oral) spray, Drug Delivery Technol., 2(5):79, July/August, 2002.
77. The buccal route for systemic delivery, World Pharm. Devel., 2:139, 2001.
78. RapidMist™ Device, www.generex.com., 2003.
79. Striant (testosterone buccal system) mucoadhesive CIII, www.rphlink.com/striant. html, October, 2003.
80. Nagai, T. and Machida, Y. Buccal delivery systems using hydrogels, Adv. Drug Del. Rev. 11(1-2):179-191, 1993.
81. Remunan-Lopez, C., Portero, A., Vila-Jato, J.L., and Alouso, M.J. Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayer devices for buccal drug delivery, J. Control. Rel., 55(2-3):143-152, 1998.
82. Park, C.R. and Munday, D.L. Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy, Int. J. Pharm., 237(1-2):215-226, 2002.
83. Bologna, W.J., Levine, H.L., Cartier, P., and de Ziegler, D. Bioadhesive progressive hydration tablets and methods of making and using the same, US Patent 6,248,358, June 19, 2001.
84. Juliano, C., Cossu, E.G., and Giuchedi, P. In vitro/in vivo studies of sodium alginate mucoadhesive buccal tablets for the local delivery of an antimicrobial agent, Cont. Rel. Soc. 30th Annual Meeting Proced. #751, 2003.
85. Arora, S., Kohi, K., and Ali, A. Microbiological evaluation of mucoadhesive buccal tablets of secnidazole against anerobic strains for the treatment of periodontal disease, Cont. Rel. Soc. 30th Annual Meeting Proced. #376, 2003.
86. Carr, D., Buchanan, E., Robertson, S., and Halliday, J.A. Controlled release buccal insert for sustaining drug concentrations in saliva, Cont. Rel. Soc. 30th Annual Meeting Proced. #541, 2003.
87. Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations, current through November 2002, http://www.fda.gov/cder/ob/default. htm, November 27, 2002.
88. Phazyme anti-gas/simethicone quick dissolve chewable tablets, Product Alert, 18(10): May 28, 2001.
89. Acid free acid-neutralizing digestive aid chewable tablets that dissolve quickly and produce no chalky or gritty texture, Product Alert, 18(10): May 28, 2001.
90. Conway, B. Chewing gum as a drug delivery system, The Drug Delivery Companies Report, Autumn/Winter: 33-35, 2003.
91. Kamimori, G.H., Karyekar, C.S., Ottersetter, R., Cox, D.S., Balkin, T.J., Belenky, G.L., and Eddington, N.D., Pharmacokinetics of diphenhydramine in healthy volunteers with a dimenhydrinate 15 mg chewing gum formulation, Int. J. Pharm., 234:159-167, 2002.
92. Hao, J., and Heng, W.S. Buccal delivery systems, Drug Dev. Ind. Pharm., 29(8):821-832, 2003.
93. Anders, R. and Merkle, H.P. Evaluation of laminated mucoadhesive patches for buccal drug delivery, Int. J. Pharm., 49:231-240, 1989.
94. Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations, current through November 2003. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs, Updated:December 22, 2003, http://www.fda.gov/cder/ob/default.htm.
95. SPI Pharma Group, PharmagumTMS. Directly compressible chewing gum delivery system. Technical bulletin, 2003.
96. Augsburger, L., Madieh, S., Mehra, D.K., Chittamuru, R., Leigh, R., and Wellman, J. The role of calcium silicate in developing directly compressible “fast melt” tablets. Poster No. W4220, American Assoc. Pharm. Sci. Annual Meeting, October 27-30, 2003.
97. Tablet & capsule trends, Nutriceutical World, 7(1):29-33, January, 2004.
98. Hadgraft, J. Perspectives on dermal and transdermal delivery, Drug Delivery Syst. Sci., 1(4):107-112, 2001.
99. Hadgraft, J. Modulation of the barrier function of the skin. Skin Pharmacol., Appl. Skin Physiol., 14 (Suppl 1): 72-81, 2001.
100. Van Weeren, R. and Gibboni, D.J. Barrier packaging as an integral part of drug delivery, Drug Delivery Technol., 2(4):48-53, June, 2002.
101. Kearny, P. et al. US Patent No. 5,631,023, Method for making freeze dried drug dosage forms, RP Scherer Corp, May, 1997.
102. Katzner et al. US Patent No. 6,155,423, Blister package and packaged tablet, CIMA Labs, December, 2000.
103. Munder, C.B., Li W., and Ream, R.L., Sildenafil citrate chewing gum formulations and methods of using the same, US patent 6,592,850, 2003.
104. Valoti, M., Frosini, M., Dragoni, S., Fusi, F., and Sgaragli, G., The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers, Methods Fund Exp. Clin. Pharm., 25:377-381, 2003.
105. Morjaria, Y., Irwin, W.J., Conway, B.R., Barnett, P.X., and Chan, R.S., Chewing gum as a drug delivery system, Proceed. Intern. Symp. Control. Rel. Bioactive Mat., 30:651, 2003.
106. Sifton, D.W., Physicians Desk Reference for Nonprescription Drugs and Dietary Supplements, PDR 24 Ed, Thompson Medical Economics, Montvale, NJ.